Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5′-hydroxylation

Drug Metabolism and Disposition

Volumn 32, Issue 1, 2004, Pages 7-9

  Ida, Izumi ^a   Miyata, Atsunori ^a   Arai, Masayuki ^a   Hirota, Mitsuyo ^a   Akimoto, Masayuki ^a   Higuchi, Shohei ^a   Kobayashi, Kaoru ^b   Chiba, Kan ^b  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5' HYDROXYLORNOXICAM; ARGININE; CYSTEINE; CYTOCHROME P450 2C9; ISOLEUCINE; LEUCINE; LORNOXICAM; UNCLASSIFIED DRUG;

ALLELE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BACULOVIRUS; CATALYSIS; DRUG CLEARANCE; DRUG HYDROXYLATION; GENOTYPE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ALLELES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARYL HYDROCARBON HYDROXYLASES; BACULOVIRIDAE; CATALYSIS; GENOTYPE; HUMANS; HYDROXYLATION; INSECTS; ISOENZYMES; KINETICS; MICROSOMES, LIVER; PIROXICAM; RECOMBINANT PROTEINS;

ANIMALIA; INSECTA; UNIDENTIFIED BACULOVIRUS;

EID: 1642498322     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.32.1.7     Document Type: Article

References (19)

1. Bhasker CR, Miners JO, Coulter S, and Birkett DJ (1997) Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 7:51-58.
2. Bonnabry P, Leemann T, and Dayer P (1996) Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur J Clin Pharmacol 49:305-308.
3. Crespi CL and Miller VP (1997) The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics 7:203-210.
4. Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, and Schwarz UI (2001) Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 60:382-387.
5. Goldstein JA (2002) Polymorphisms in the human CYP2C subfamily. Drug Metab Rev 34 (Suppl 1):5.
6. Hermida J, Zarza J, Alberca I, Montes R, Lopez ML, Molina E, and Rocha E (2002) Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol. Blood 99:4237-4239.
7. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, and Goldstein JA (2001) Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 11:803-808.
8. Lee CR, Pieper JA, Hinderliter AL, Blaisdell JA, and Goldstein JA (2002) Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C9*1 heterozygotes. Clin Pharmacol Ther 72:562-571.
9. Lewis DFV (2002) Homology modeling of human CYP2 family enzymes based on the CYP2C5 crystal structure. Xenobiotica 32:305-323.
10. Miners JO and Birkett DJ (1998) Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525-538.
11. Miners JO, Coulter S, Birkett DJ, and Goldstein JA (2000) Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes. Pharmacogenetics 10:267-270.
12. Radhofer-Welte S and Rabasseda X (2000) Lornoxicam, a new potent NSAID with an improved tolerability profile. Drugs Today 36:55-76.
13. Ravic M, Johnston A, Turner P, Takacs F, and Rosenow DE (1991) The effect of repeated oral doses of lornoxicam on antipyrine elimination in normal human volunteers. Hum Exp Toxicol 10:375-377.
14. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, and Korzekwa KR (1994) Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4:39-42.
15. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang Z-Y, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, and Goldstein JA (1996) The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6:341-349.
16. Suwa T, Urano H, Shinohara Y, and Kokatsu J (1993) Simultaneous high-performance liquid chromatographic determination of lornoxicam and its 5′-hydroxy metabolite in human plasma using electrochemical detection. J Chromatgr 617:105-110.
17. 359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 10:95-104.
18. Turner P and Johnston A (1990) Clinical pharmacokinetic studies with lornoxicam. Postgrad Med J 66:s28-s29.
19. Yamazaki H, Inoue K, and Shimada T (1998) Role of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. Xenobiotica 28:103-115.